February 2017 in “대한피부과학회지” Combining low-dose dutasteride with finasteride improved a man's hair loss.
25 citations
,
May 2018 in “Clinical & Translational Oncology” New melanoma treatments can cause skin side effects, including skin cancer and rashes, but combining treatments may reduce these risks.
June 2022 in “Journal of The European Academy of Dermatology and Venereology” Microneedling with topical dutasteride improves hair growth in men with hair loss and is safe to use.
22 citations
,
November 2002 in “Clinical journal of oncology nursing” Arsenic trioxide effectively treats relapsed acute promyelocytic leukemia with manageable side effects.
Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
November 2025 in “The Journal of Dermatology” Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.
1 citations
,
May 2017 in “Journal of Clinical Oncology” Topical calcitriol is safe for preventing hair loss during chemotherapy.
January 2015 in “프로그램북(구 초록집)” Dutasteride is effective and safe for treating common hair loss, and it's more potent than finasteride, leading to better hair growth and thickness.
September 2022 in “XXXIX Congresso Brasileiro de Reumatologia” Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
6 citations
,
August 2020 in “Oncology nursing forum” Minocycline reduces acne rash, pyridoxine lowers hand-foot syndrome risk, and scalp cooling lessens hair loss from cancer treatments.
1 citations
,
November 2018 in “Therapeutic Delivery” New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
4 citations
,
February 2019 in “Revista da Associação Médica Brasileira” FOLFOX6 chemotherapy effectively reduces VEGF levels and improves quality of life in advanced colorectal cancer patients.
August 2009 in “Australian Prescriber” Dutasteride is approved to help manage prostate enlargement.
April 2026 in “Frontiers in Medicine” Enfortumab vedotin can cause skin issues, especially in older males, needing early monitoring.
5 citations
,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
May 2008 in “Trends in Urology Gynaecology & Sexual Health” Loop diuretics may double bone loss in elderly men, finasteride lowers prostate cancer risk but may increase high-grade tumors, abarelix reduces testosterone quickly, and transdermal testosterone offers minimal sexual benefit for women.
February 2023 in “European Journal of Dermatology” The document concludes that injecting dutasteride into the skin (mesotherapy) can effectively treat common hair loss in both men and women.
August 2016 in “PolyPublie (École Polytechnique de Montréal)” Doxorubicin causes heart damage, so early detection and monitoring are important during chemotherapy.
March 2026 in “Journal of Personalized Medicine” Genetic differences affect breast cancer treatment success with tamoxifen in South African patients.
Individualized treatments may help manage Dercum's disease symptoms.
5 citations
,
January 2012 in “JBI Library of Systematic Reviews” Avemar may help in cancer treatment, but its effectiveness isn't proven yet.
March 2024 in “Clinical, cosmetic and investigational dermatology” Upadacitinib may effectively treat alopecia areata without side effects.
January 2024 in “Journal of dermatology and skin science” Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.
8 citations
,
September 2015 in “Journal of the European Academy of Dermatology and Venereology” Hair and scalp pain is more common and severe in breast cancer patients on chemotherapy than those on tamoxifen.
30 citations
,
March 2007 in “Expert opinion on drug safety” Cetuximab often causes skin rashes, and managing these is important for cancer treatment.
2 citations
,
November 2021 in “ACG Case Reports Journal” Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.
31 citations
,
January 1989 in “The Prostate/The prostate” Estradiol and castration reduced prostate cancer development in rats when applied at early stages, but were ineffective after cancer was established.
41 citations
,
April 2012 in “Journal of The European Academy of Dermatology and Venereology” Dutasteride-containing mesotherapy effectively treats female hair loss, improving density and thickness with minimal side effects.
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.